secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001104659-24-087273
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q2 revenue up 58% to $413.4M, loss narrows to $37.5M, guides higher
--------------------------------------------------------------------------

- Revenue $413.4M (+58.1% YoY); product revenue $411.4M (+59.3%); gross margin 58.8% vs 45.2%.
- Net loss $37.5M ($0.30 loss per share) vs $110.8M ($0.97) YoY; operating loss $43.9M vs $112.4M.
- Processed ~760,300 tests (+23.2%); oncology tests up 50.2% to ~125,400.
- Achieved positive cash flow ~$3.3M; FY 2024 revenue guidance raised to $1.49-$1.52B.
- Cash and investments $887.1M; outstanding debt $364.0M as of June 30, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465924087273/0001104659-24-087273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465924087273/tm2420614d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-087273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer